N
32.99
0.18 (0.55%)
| Penutupan Terdahulu | 32.81 |
| Buka | 31.65 |
| Jumlah Dagangan | 725,310 |
| Purata Dagangan (3B) | 787,736 |
| Modal Pasaran | 3,793,039,360 |
| Harga / Jualan (P/S) | 51.43 |
| Harga / Buku (P/B) | 4.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -2,314.47% |
| EPS Cair (TTM) | -1.84 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 112.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 19.98 |
| Aliran Tunai Operasi (OCF TTM) | -140.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -99.00 M |
| Pulangan Atas Aset (ROA TTM) | -18.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NewAmsterdam Pharma Company N.V | Menurun | Menaik |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.75 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.39% |
| % Dimiliki oleh Institusi | 111.32% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 16,943,774 |
| Fcpm Iii Services B.V. | 31 Dec 2025 | 9,198,900 |
| Viking Global Investors Lp | 31 Dec 2025 | 4,203,567 |
| Jennison Associates Llc | 31 Dec 2025 | 3,489,221 |
| Duquesne Family Office Llc | 31 Dec 2025 | 3,070,146 |
| Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2025 | 2,869,565 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 2,776,222 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Needham, 45.50%) | Beli |
| Median | 47.00 (42.47%) | |
| Rendah | 45.00 (Guggenheim, 36.41%) | Beli |
| Purata | 46.67 (41.47%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 34.78 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 19 Feb 2026 | 45.00 (36.40%) | Beli | 34.63 |
| Needham | 18 Feb 2026 | 48.00 (45.50%) | Beli | 35.76 |
| RBC Capital | 21 Jan 2026 | 47.00 (42.47%) | Beli | 33.94 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Feb 2026 | Pengumuman | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Feb 2026 | Pengumuman | NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit |
| 09 Jan 2026 | Pengumuman | NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |